Business Wire

CA-SYSDIG,-INC.

13.1.2021 13:02:34 CET | Business Wire | Press release

Share
Sysdig Usage Report Finds Shifting Container Security Left is Not Enough

Sysdig, Inc., the secure DevOps leader, today announced findings from its Sysdig 2021 Container Security and Usage Report. While usage reveals organizations are shifting left by scanning images during the build phase, DevOps teams are still leaving their environments open to attack. The report also looks at trends, finding a 310 percent growth in container density since 2017.

The fourth annual report reveals how global Sysdig customers of all sizes and across industries are using and securing container environments. This real-world, real-time data provides insight into usage of the nearly one billion containers Sysdig customers run yearly, including security risks, container utilization, and services used. Read the Sysdig 2021 Container Security and Usage blog .

Among its findings, the report states that while 74 percent of customers are scanning before deployment, still more than half (58 percent) of containers are running as root. There are some containers that should run as root—security and system daemons for example—but this is a small portion of total containers. These risky configurations leave easy access to potentially compromise the system and access sensitive data. This finding stresses the need for security throughout the lifecycle of a container image—fixing vulnerabilities is not enough.

Highlights From the Report

Container density grows 170% since 2018

Over the past three years, the median number of containers-per-host more than doubled from 15 in 2018 to 41 today, indicating a growth in efficiency and a shift in cost savings as containers mature. This reveals a continued focus on optimization.

Prometheus continues to grow, 35% YoY

Open source adoption is broader than just Kubernetes as organizations are shifting toward Prometheus as the standard approach to monitoring container environments. The use of Prometheus metrics among Sysdig customers grew 35 percent year-over-year.

Docker down, containerd and CRI-O up 4X

In 2017, Docker represented 99 percent of containers in use at that time. Today, that number has fallen to 50 percent, down from 79 percent in October 2019. While Docker revolutionized containers, organizations are rapidly switching to newer runtimes like containerd and CRI-O.

21% of containers live less than 10 seconds

The ephemeral nature of containers is a unique efficiency advantage, yet it can be a challenge in managing issues around security, health, and performance. The short life of containers reaffirms the need for container-specific tools for security and monitoring. For example, organizations need metric collection with intervals of less than 10 seconds and a detailed record of what occurred when the container was alive.

“With the high-profile breaches we are seeing and the accelerated adoption of containers in production, the container security risk is now on the radar of CISOs. Across millions of containers that we have studied, it’s clear that organizations are shifting security left, but they are neglecting critical best practices,” said Suresh Vasudevan, chief executive officer of Sysdig. “Container security has to span the entire software development lifecycle. Until organizations fix risky configurations, protect their runtime environments, and invest in container forensics, we will see an increase in container security breaches. I expect we will see several high-impact breaches before we release our next report.”

Other Interesting Findings

  • Falco, the open source runtime project for cloud-native environments created by Sysdig and donated to the CNCF, has seen a 300 percent increase in Docker Hub downloads over the last year.
  • The use of golang increased to 66 percent, a 470 percent jump since last year.
  • 63 percent of container images are replaced within two weeks or less, signifying a more frequent code deployment rate.

Learn More About this Report

About Sysdig

Sysdig is driving the secure DevOps movement, empowering organizations to confidently secure containers, Kubernetes, and cloud services. With the Sysdig Secure DevOps Platform, cloud teams secure the build pipeline, detect and respond to runtime threats, continuously validate compliance, and monitor and troubleshoot cloud infrastructure and services. Sysdig is a SaaS platform, built on an open source stack that includes Falco and sysdig OSS, the open standards for runtime threat detection and response. Hundreds of companies rely on Sysdig for container and Kubernetes security and visibility. Learn more at www.sysdig.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye